Your session is about to expire
← Back to Search
Minnelide + Osimertinib for Lung Cancer
Study Summary
This trial is testing the side effects and best dose of minnelide given with osimertinib to treat non-small cell lung cancer that has spread and has a mutation in the EGFR gene.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 60 Patients • NCT03853551Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor has a specific EGFR mutation sensitive to certain treatments.I have not taken strong CYP3A4 drugs in the last 14 days.My liver function test is within the required range.My blood clotting time is within the target range for my anticoagulant therapy.I have a history of HIV or hepatitis B/C.My blood clotting time is within the normal range and I'm not on blood thinners.I have a serious health condition that is not under control.Your albumin level in your blood needs to be at least 3.0 g/dL within 14 days before starting the treatment.I have not taken herbal or alternative medicines like turmeric or CBD in the last 7 days.I am currently experiencing diarrhea.I am a woman who can have children and have a recent negative pregnancy test.I have had brain metastases but am now symptom-free, off steroids for a week, and finished radiation 2 weeks ago.Your liver enzyme levels must be within a certain range before starting the treatment, especially if you have cancer that has spread to the liver.Your platelet count needs to be at least 100,000 per cubic millimeter within 14 days before starting the treatment.I have been diagnosed with congenital long QT syndrome.I have severe heart issues, recent heart attack, irregular heartbeat, or signs of poor blood flow on an ECG.My cancer has worsened despite taking osimertinib.I am 18 years old or older.My lung cancer cannot be treated with surgery or radiation aimed at a cure.Your hemoglobin level needs to be at least 9 grams per deciliter within 14 days before starting the treatment.I have a condition that affects how my body absorbs nutrients.Your liver enzyme levels need to be below a certain limit before starting the treatment, unless you have liver metastases, in which case they can be slightly higher.Your white blood cell count is at least 1,500 per cubic millimeter.I haven't had biological or immunotherapy in the last 21 days.My blood clotting time is within the normal range and I'm not on blood thinners.I am able to care for myself but may not be able to do active work.You have a tumor that can be measured using specific guidelines.My blood clotting time is within the target range for my anticoagulant therapy.I had cancer before, but it was either treated over 5 years ago, was a non-dangerous skin cancer, or a low-grade prostate cancer.I haven't taken clarithromycin, loperamide, or ondansetron in the last 7 days.Your heart's QT corrected interval is less than or equal to 470 milliseconds.I haven't taken specific heart rhythm medications in the last 14 days.I have taken osimertinib at 80 mg daily without severe side effects.I do not have any ongoing serious infections needing treatment.You have had allergic reactions to drugs that are similar to the study drug.I haven't had cancer treatments or experimental therapy in the last 21 days.I am not pregnant or breastfeeding.My kidney function, measured by creatinine levels or clearance, is within the normal range.Your bilirubin levels should not be higher than 1.5 times the upper limit of normal, unless you have Gilbert's disease. If you have Gilbert's disease, your bilirubin levels should be lower than 3 times the upper limit of normal.I have recovered from cancer treatment side effects, except for hair loss and mild nerve pain.I can swallow and keep down pills.I am a man who will not father a child or donate sperm during and for 6 months after the study.Your recent urine test should not show any major problems.
- Group 1: Treatment (minnelide, osimertinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment available for this research trial at present?
"Yes, data hosted on clinicaltrials.gov affirms that this clinical research is actively welcoming participants. The trial was first made available for review on March 7th 2022 and has been recently refreshed as of August 2nd 2022. 30 individuals will be accepted at the single recruitment site."
Is this an innovative research endeavor?
"Currently, there are 101 active studies for Osimertinib that span 51 countries and 1059 cities. This medication was initially trialled in 2013, with AstraZeneca overseeing a Phase 1 & 2 trial involving 603 patients. Since then, 72 further investigations have been launched into this drug's potential efficacy."
What research has been conducted to explore the efficacy of Osimertinib?
"Presently, there are 101 studies for Osimertinib with 17 in the latter stage of testing. These trials can be found predominantly in Uniondale, NY as well as across 4702 other sites internationally."
To what extent can Osimertinib cause harm to individuals?
"The limited clinical data available surrounding osimertinib's safety and efficacy gives it a score of 1 on our scale."
How many participants are joining this research project?
"Affirmative. According to clinicaltrials.gov, this research trial is actively recruiting participants and has been since March 7th 2022. A total of 30 test subjects need to be sourced from a single medical facility before the last update on August 2nd 2022."
Share this study with friends
Copy Link
Messenger